Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction

Circulation: Heart Failure

Volumn 5, Issue 6, 2012, Pages 750-758

  Vaduganathan, Muthiah ^a   Ambrosy, Andrew P ^b   Greene, Stephen J ^c   Mentz, Robert J ^c,e,f   Subacius, Haris P ^d   Maggioni, Aldo P ^g   Swedberg, Karl ^h   Nodari, Savina ⁱ   Zannad, Faiez ^j   Konstam, Marvin A ^k   Butler, Javed ^l   Gheorghiade, Mihai ^m  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Center for Cardiovascular Innovation   (United States)

^d Division of Cardiology   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f DUKE UNIVERSITY   (United States)

^g ANMCO RESEARCH CENTER   (Italy)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j UNIVERSITÉ DE LORRAINE   (France)

^k TUFTS MEDICAL CENTER   (United States)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Heart failure; Immune system; Lymphocytes; Prognosis

Indexed keywords

SODIUM; TOLVAPTAN;

AGED; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; KIDNEY FAILURE; LOG RANK TEST; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); SODIUM BLOOD LEVEL;

AGED; BENZAZEPINES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INPATIENTS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; STROKE VOLUME; VASOPRESSINS;

EID: 84873654468     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.970525     Document Type: Article

References (34)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell'italia LJ, White M, Gheorghiade M. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: A propensity-matched study. J Card Fail. 2008;14:211-218.
3. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768-777.
4. Acanfora D, Gheorghiade M, Trojano L, Furgi G, Pasini E, Picone C, Papa A, Iannuzzi GL, Bonow RO, Rengo F. Relative lymphocyte count: A prognostic indicator of mortality in elderly patients with congestive heart failure. Am Heart J. 2001;142:167-173.
5. Charach G, Grosskopf I, Roth A, Afek A, Wexler D, Sheps D, Weintraub M, Rabinovich A, Keren G, George J. Usefulness of total lymphocyte count as predictor of outcome in patients with chronic heart failure. Am J Cardiol. 2011;107:1353-1356.
6. Huehnergarth KV, Mozaffarian D, Sullivan MD, Crane BA, Wilkinson CW, Lawler RL, McDonald GB, Fishbein DP, Levy WC. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol. 2005;95:1492-1495.
7. Sakatani T, Hadase M, Kawasaki T, Kamitani T, Kawasaki S, Sugihara H. Usefulness of the percentage of plasma lymphocytes as a prognostic marker in patients with congestive heart failure. Jpn Heart J. 2004;45:275-284.
8. Rudiger A, Burckhardt OA, Harpes P, Müller SA, Follath F. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med. 2006;24:451-454.
9. Núñez J, Núñez E, Miñana G, Sanchis J, Bodí V, Rumiz E, Palau P, Olivares M, Merlos P, Bonanad C, Mainar L, Llàcer A. Effectiveness of the relative lymphocyte count to predict one-year mortality in patients with acute heart failure. Am J Cardiol. 2011;107:1034-1039.
10. Milo-Cotter O, Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Edwards C, Weatherley BD, Greenberg B, Filippatos G, Unemori E, Teichman SL, Cotter G. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: Results from the Pre-RELAX-AHF study. Cardiology. 2010;117:190-196.
11. Milo-Cotter O, Felker GM, Uriel N, Kaluski E, Edwards C, Rund MM, Weatherley BD, Cotter G. Patterns of leukocyte counts on admissions for acute heart failure-presentation and outcome-results from a community based registry. Int J Cardiol. 2011;148:17-22.
12. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation. 2006;113:1424-1433.
13. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-356.
14. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC. Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156:662-673.
15. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
16. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005;11:260-269.
17. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
18. Bekwelem W, Lutsey PL, Loehr LR, Agarwal SK, Astor BC, Guild C, Ballantyne CM, Folsom AR. White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2011;21:739-748.
19. Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study. Eur Heart J. 2012;33:523-530.
20. Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CG, Thomson SP, Gibbons RJ. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation. 1998;97:19-22.
21. Ommen SR, Hammill SC, Gibbons RJ. The relative lymphocyte count predicts death in patients receiving implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2002;25:1424-1428.
22. Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: Analysis from the EVEREST trial. Heart Fail Rev. 2012;17:485-509.
23. Castelino DJ, McNair P, Kay TW. Lymphocytopenia in a hospital population-what does it signify? Aust N Z J Med. 1997;27:170-174.
24. Battin DL, Ali S, Shahbaz AU, Massie JD, Munir A, Davis RC Jr, Newman KP, Weber KT. Hypoalbuminemia and lymphocytopenia in patients with decompensated biventricular failure. Am J Med Sci. 2010;339:31-35.
25. Peschel T, Schönauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5:609-614.
26. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26:2368-2374.
27. von Haehling S, Schefold JC, Jankowska E, Doehner W, Springer J, Strohschein K, Genth-Zotz S, Volk HD, Poole-Wilson P, Anker SD. Leukocyte redistribution: Effects of beta blockers in patients with chronic heart failure. PLoS ONE. 2009;4:e6411.
28. Castro A, Bemer V, Nóbrega A, Coutinho A, Truffa-Bachi P. Administration to mouse of endotoxin from gram-negative bacteria leads to activation and apoptosis of T lymphocytes. Eur J Immunol. 1998;28:488-495.
29. Maisel AS, Knowlton KU, Fowler P, Rearden A, Ziegler MG, Motulsky HJ, Insel PA, Michel MC. Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Invest. 1990;85:462-467.
30. Thomson SP, McMahon LJ, Nugent CA. Endogenous cortisol: A regulator of the number of lymphocytes in peripheral blood. Clin Immunol Immunopathol. 1980;17:506-514.
31. McDonagh TA, Komajda M, Maggioni AP, Zannad F, Gheorghiade M, Metra M, Dargie HJ. Clinical trials in acute heart failure: Simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. Eur J Heart Fail. 2011;13:1253-1260.
32. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
33. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
34. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, Capodilupo R. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol. 2011;107:433-438.